Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | USP1 | O94782 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.33 |
| ▸ | TLK2 | Q86UE8 | 2/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4758717 | 1.00 | KDR (0.41) | KDRFGFR1BRAFNTRK1POLB | |
| SCHEMBL3575231 | 0.91 | KDR (0.44) | KDRFGFR1BRAFNTRK1POLB | |
| SCHEMBL3575229 | 0.91 | KDR (0.44) | KDRFGFR1BRAFNTRK1POLB | |
| SCHEMBL3581069 | 0.90 | KDR (0.41) | KDRFGFR1BRAFNTRK1POLB | |
| SCHEMBL3581074 | 0.90 | KDR (0.41) | KDRFGFR1BRAFNTRK1POLB | |
| SCHEMBL3572736 | 0.89 | KDR (0.45) | KDRFGFR1BRAFNTRK1POLB | |
| SCHEMBL3572738 | 0.89 | KDR (0.45) | KDRFGFR1BRAFNTRK1POLB | |
| SCHEMBL3577932 | 0.86 | KDR (0.46) | KDRFGFR1BRAFNTRK1KMT2A | |
| SCHEMBL3577933 | 0.86 | KDR (0.46) | KDRFGFR1BRAFNTRK1KMT2A | |
| SCHEMBL3571787 | 0.85 | KDR (0.48) | KDRFGFR1BRAFNTRK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1902025-A1 | KINASE INHIBITORS | Allergan, Inc. (US) | 2008-03-26 | — | — | EP | claimed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | claimed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032478-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | KDR 226/4885FGFR1 171/4885BRAF 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.